NASDAQ:NVCR - Novocure Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $50.38 +0.08 (+0.16 %) (As of 05/20/2019 06:19 AM ET)Previous Close$50.38Today's Range$49.7686 - $51.3552-Week Range$26.02 - $56.67Volume317,729 shsAverage Volume447,413 shsMarket Capitalization$4.82 billionP/E RatioN/ADividend YieldN/ABeta3.04 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey. Receive NVCR News and Ratings via Email Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR Previous Symbol CUSIPN/A CIK1645113 Webwww.novocure.com Phone44-0-15-3475-6700Debt Debt-to-Equity Ratio1.27 Current Ratio4.73 Quick Ratio4.39Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$248.07 million Price / Sales19.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book38.17Profitability EPS (Most Recent Fiscal Year)($0.69) Net Income$-63,560,000.00 Net Margins-20.42% Return on Equity-47.23% Return on Assets-16.47%Miscellaneous EmployeesN/A Outstanding Shares95,770,000Market Cap$4.82 billion Next Earnings Date7/25/2019 (Estimated) OptionableOptionable Novocure (NASDAQ:NVCR) Frequently Asked Questions What is Novocure's stock symbol? Novocure trades on the NASDAQ under the ticker symbol "NVCR." How were Novocure's earnings last quarter? Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, May, 2nd. The medical equipment provider reported ($0.13) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.13). The medical equipment provider earned $73.31 million during the quarter, compared to analysts' expectations of $72.85 million. Novocure had a negative net margin of 20.42% and a negative return on equity of 47.23%. The firm's revenue was up 40.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.23) EPS. View Novocure's Earnings History. When is Novocure's next earnings date? Novocure is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Novocure. What price target have analysts set for NVCR? 7 brokers have issued twelve-month price objectives for Novocure's shares. Their forecasts range from $36.00 to $63.00. On average, they expect Novocure's stock price to reach $48.7143 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View Analyst Price Targets for Novocure. What is the consensus analysts' recommendation for Novocure? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure. What are Wall Street analysts saying about Novocure stock? Here are some recent quotes from research analysts about Novocure stock: 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (3/19/2019) 2. Mizuho analysts commented, "We currently model initial revenue for this indication starting in late 2019." (12/6/2018) Has Novocure been receiving favorable news coverage? Media headlines about NVCR stock have trended neutral recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novocure earned a news impact score of 0.5 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Who are some of Novocure's key competitors? Some companies that are related to Novocure include ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), ICU Medical (ICUI), Integra Lifesciences (IART), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Merit Medical Systems (MMSI) and Cantel Medical (CMD). What other stocks do shareholders of Novocure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and Rewalk Robotics (RWLK). Who are Novocure's key executives? Novocure's management team includes the folowing people: Asaf Danziger, Chief Executive Officer & DirectorMike Ambrogi, Chief Operating OfficerWilco Groenhuysen, CFO & Chief Accounting OfficerEilon D. Kirson, Chief Science Officer, Head-Research & DevelopmentUri Weinberg, Vice President-Clinical Development Who are Novocure's major shareholders? Novocure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.90%), Baillie Gifford & Co. (8.41%), BlackRock Inc. (5.02%), Renaissance Technologies LLC (1.94%), Macquarie Group Ltd. (1.21%) and Wells Fargo & Company MN (1.10%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Institutional Ownership Trends for Novocure. Which institutional investors are selling Novocure stock? NVCR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Westfield Capital Management Co. LP, TimesSquare Capital Management LLC, Peregrine Capital Management LLC, Morgan Stanley, Rhenman & Partners Asset Management AB, Macquarie Group Ltd. and Hartline Investment Corp. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti. View Insider Buying and Selling for Novocure. Which institutional investors are buying Novocure stock? NVCR stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Wells Fargo & Company MN, Granite Investment Partners LLC, Federated Investors Inc. PA and Spark Investment Management LLC. View Insider Buying and Selling for Novocure. How do I buy shares of Novocure? Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novocure's stock price today? One share of NVCR stock can currently be purchased for approximately $50.38. How big of a company is Novocure? Novocure has a market capitalization of $4.82 billion and generates $248.07 million in revenue each year. The medical equipment provider earns $-63,560,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. What is Novocure's official website? The official website for Novocure is http://www.novocure.com. How can I contact Novocure? Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected] MarketBeat Community Rating for Novocure (NASDAQ NVCR)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 337 (Vote Outperform)Underperform Votes: 307 (Vote Underperform)Total Votes: 644MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Moving Average Convergence Divergence (MACD) Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.